Engineered extracellular vesicles as nanosponges for lysosomal degradation of PCSK9
Quick Facts
- Publication title: Engineered extracellular vesicles as nanosponges for lysosomal degradation of PCSK9
- Journal: Mol Ther
- Year: 2024
- DOI: 10.1016/j.ymthe.2024.11.034
- PMID/PMCID: 39604267; PMC11853006
Research overview
In this study, extracellular vesicles (EVs) were engineered to nanosponges, which could efficiently adsorb and deliver PCSK9 into lysosomes for degradation. In this study, extracellular vesicles (EVs) were engineered to nanosponges, which could efficiently adsorb and deliver PCSK9 into lysosomes for degradation.
Key findings
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in the degradation of the low-density lipoprotein receptor (LDLR), and PCSK9 inhibition emerges as an attractive strategy for atherosclerosis management.
In this study, extracellular vesicles (EVs) were engineered to nanosponges, which could efficiently adsorb and deliver PCSK9 into lysosomes for degradation.
Briefly, nanosponges were engineered by modifying EVs with EGF-A/PTGFRN fusion protein (PCSK9 binding domain EGF-A from the mutant LDLR with higher affinity was fused to the C terminus of prostaglandin F2 receptor negative regulator).
The modification endowed the EVs with hundreds of EGF-As displayed on the surface, and thus the capacity to adsorb PCSK9 efficiently.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, cargo loading; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Echosome®, Research Reagents & Tools
Related services and capabilities: Cell-Culture Supernatant EV Isolation & Purification, Small RNA / Cargo Loading, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Engineered extracellular vesicles as nanosponges for lysosomal degradation of PCSK9 Molecular therapy. 2024. DOI: 10.1016/j.ymthe.2024.11.034. PMID/PMCID: 39604267; PMC11853006.